CD8A and lung carcinoma: Insights from mIF performed in lung cancer suggest that higher densities of CD8+ T-cells and PD-L1+ cells, especially when co-expressed, are significantly associated with significantly longer PFS and OS when patients are treated with immunochemotherapy [42,43].